IDStewardship

JUNE 12, 2022

In this post an infectious diseases pharmacist identifies and discusses 5 things learned from #ASMicrobe 2022 – through Twitter. Authored by: Timothy P. Gauthier, Pharm.D., BCPS, BCIDP. Article posted 13 June 2022. There are many scientific meetings to go to these days. For infectious diseases enthusiasts, just a few that come to mind include IDweek, ECCMID, ASMicrobe, ACCP, and MAD-ID.

Vaccines 130

Vaccines 130

pharmaphorum

JUNE 12, 2022

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has continued to show impressive results in clinical trial, with an update at the EHA congress showing long-term effects on the symptoms of both beta thalassaemia and sickle cell disease. New data from the CLIMB-111, CLIMB-121, and CLIMB-131 presented in a late breaker at the EHA yesterday came from 75 patients with thalassaemia and SCD who had been treated with CTX001 (exagamglogene autotemcel or exa-cel) for between around

Chemotherapy 59

Chemotherapy FDA 59

Med Ed 101

JUNE 12, 2022

The NAPLEX Exam will test your ability to recognize mechanisms of action, adverse drug reactions, indications, drug interactions, clinical pearls, and contraindications. While memorizing these items is critical, one must first be able to correlate the brand and generic name. The NAPLEX will test your knowledge of drug names. This free NAPLEX brand generic quiz […].

40

40

pharmaphorum

JUNE 12, 2022

bluebird bio started last week on tenterhooks, as FDA advisors cast their eyes over data for two gene therapy candidates that are key to its future as a commercially viable concern. By the end of the week, it was two for two, with both recommended for approval by a unanimous vote. Thursday saw the Cellular, Tissue and Gene Therapies advisory committee back elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD) – see our report here – and the following day it was the turn of b

FDA 59

FDA 59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.